The Norwegian Medicines Agency and the Norwegian Institute of Public Health (NIPH) had received three serious cases of blood clots in younger people who received the AstraZeneca vaccine. There was a report of one death as well on March 12.
Blood clots due to AstraZeneca vaccine
Chief physician and Professor Pål Andre Holme told to the VG that the reason for the condition of their patients has been found. He was working to figure out the cause of severe blood clots among health workers aged below 50. They had to get hospitalized after receiving the AstraZeneca vaccine for Covid-19.
The theory on which the experts were working revealed it was the vaccine that stimulated a sudden and powerful immune response.
“Our theory that this is a powerful immune response which most likely was caused by the vaccine has been found. In collaboration with experts in the field from the University Hospital of North Norway HF, we have found specific antibodies against blood platelets that can cause these reactions, and which we know from other fields of medicine, but then with medical drugs as the cause of the reaction”, described the chief physician.
Holme was confident that the cause of those rare blood clotting cases has been found. He said only the vaccine could explain why those patients had this immune response.
In a reply to a question that how Holme knows that the vaccine is the reason behind the immune response, he said:
“There is nothing in the patient history of these individuals that can give such a powerful immune response. I am confident that the antibodies that we have found are the cause. And I see no other explanation than it being the vaccine which triggers it.”
Hospitalized health workers
The three hospitalized health workers had a very rare condition:
- Acute pain
- Blood clots in their stomachs and brains
- Bleedings and low levels of platelets
The Norwegian Medicines Agency avoids commenting on the results from Oslo University Hospital. Whereas, the Safety Committee of the European Medicines Agency might bring a conclusion later today.
AstraZeneca also refused to say a word on the conclusion of the Norwegian experts.
“We await the decisions of the EMA later today before we will comment on this,” said Media Relations Director, Hägerstrand.